This recently published review from @EuroInterventio provides a comprehensive overview of the current state of #AorticRegurgitation, from prevalence and mechanism to diagnosis and treatment, including emerging therapies. Read more: https://lnkd.in/gfp5Rscb
JenaValve Technology, Inc.
Medical Equipment Manufacturing
Irvine, CA 9,395 followers
Aortic regurgitation is different. So is our valve.
About us
JenaValve is a medical device company developing the first transcatheter heart valve technology that is uniquely designed for the minimally invasive treatment of aortic regurgitation (AR). The JenaValve Trilogy Heart Valve System is the first and only device currently approved in the EU for the treatment of severe, symptomatic aortic regurgitation in patients that are deemed high-risk for surgical aortic valve replacement. The Trilogy System is also CE-Mark approved for treatment of severe, symptomatic aortic stenosis. In the US, JenaValve has completed enrollment of the ALIGN-AR IDE Clinical Trial which will support a future PMA submission. If approved, the Trilogy System would become the first and only TAVR system in the US indicated for the treatment of symptomatic, severe AR. JenaValve is headquartered in Irvine, California with offices in Leeds, U.K. and Munich, Germany.
- Website
-
http://www.jenavalve.com
External link for JenaValve Technology, Inc.
- Industry
- Medical Equipment Manufacturing
- Company size
- 51-200 employees
- Headquarters
- Irvine, CA
- Type
- Privately Held
- Founded
- 2013
Locations
-
Primary
4 Cromwell
Suite 100
Irvine, CA 92618, US
Employees at JenaValve Technology, Inc.
Updates
-
Presented at #NYValves2024: A Forward Outlook on TAVR for Aortic Regurgitation This @TCTMD satellite symposium delves into the challenges of AR evaluation, the future of TAVR for AR & includes presentations from @RigolinVera, Raj Makkar, & @MattiAdam_MD. https://lnkd.in/gAFYEt37
-
Missed our Satellite Symposium at #NYValves2024? You can check out this session examining the future of #AorticRegurgitation treatment, and the need for a dedicated #TAVR solution. Link below: https://lnkd.in/gKu9Hve9 @CRFHeart2024
-
Late-breaking trials announced for #TCT2024! 2-year outcomes of the ALIGN-AR pivotal study to be presented on Tuesday, October 29th. Check out all the late-breaking science here: https://lnkd.in/gVygGcHu
CRF Announces TCT 2024 Late-Breaking Clinical Trials and Science - CRF
crf.org
-
From the multicenter #PURPOSE study: the dedicated Trilogy valve demonstrated 98% technical success (VARC-3) vs 81% with off-label THVs in patients with pure aortic regurgitation. https://lnkd.in/gJek-GJi
Performance of Purpose-Built vs Off-Label Transcatheter Devices for Aortic Regurgitation: The PURPOSE Study GET ACCESS
jacc.org
-
From #CVI2024, this CVITV interview between Dr Chadi Alraies, MD FACC FSCAI and Drs Nadira Hamid, Nick Amoroso MD, FACC, FSCAI discusses the importance of accurate echo screening for #AorticRegurgitation and the results of the ALIGN-AR Trial, the first pivotal study on a dedicated #TAVR device for AR. https://lnkd.in/gEuC8T4Q
Are We There Yet? TAVR for AR, with Chadi Alraies, MD, Nadira Hamid, MD & Nicholas Amoroso, MD
https://www.youtube.com/
-
From #NYValves2024: This @TCTMD interview between Drs Robert Bonow and @laurenranard covers current parameters for AR severity and increasing enthusiasm towards future dedicated TAVR solutions for AR. Check it out now: https://lnkd.in/gQGzd4cp
Advances in the Management of AR
tctmd.com
-
Now published in Catheterization and Cardiovascular Interventions (CCI): patients with moderate or greater #aorticregurgitation experience poor clinical outcomes, yet most do not receive treatment. This study assessed over 1 million patients from 25 US institutions and classified them by severity of AR as documented in echo reports. Fewer than 50% of patients with severe aortic regurgitation, as diagnosed by echo, received treatment within 2 years of their index diagnosis, and only 19.4% of patients diagnosed with moderate-to-severe AR received treatment. Unfortunately, for patients who did not receive AVR, mortality at 2 years was 20.7% for those diagnosed with severe AR, and 18.9% for patients with moderate-to-severe AR. Finally, additional analysis showed that in patients diagnosed with moderate AR with a documented measure of LV dilation (in this case, LVESDi > 25mm/m2), mortality at 2 years increased to 34.3% - which warrants discussion regarding the “moderate” diagnosis. This study reinforces the importance of treatment for patients with AR and raises further questions on the assessment of severity and the timing of intervention. Are we diagnosing AR appropriately? Would AR patients benefit from earlier referral and treatment? We look forward to further studies that will help us better understand the clinical journey of patients with aortic regurgitation! @Nick Amoroso MD, FACC, FSCAI @Vinod Thourani, @Duane Pinto, MD MPH, @Linda Gillam, MD, MPH, @egnite Health https://lnkd.in/g3CsiyEH
Clinical journey for patients with aortic regurgitation: A retrospective observational study from a multicenter database
onlinelibrary.wiley.com
-
We are proud to announce that we have reached an agreement with Edwards Lifesciences to acquire JenaValve. The mission remains: to develop the world’s first transcatheter heart valve technology uniquely designed for patients with #AorticRegurgitation. Together with Edwards, the world’s leader in #TAVR, we are now closer to addressing this global unmet need. Read the press release here: https://bit.ly/3Sn7eiq
Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix
-
How does the Trilogy THV compare to off-label valves in treating patients with #AorticRegurgitation? The #PURPOSE Study showed better procedural success and fewer periprocedural complications with the dedicated Trilogy valve compared to off-label THVs. https://lnkd.in/gJek-GJi